Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

NCT06972628 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer Patients With Bone Metastasis
Prostate Cancer (CRPC)
Prostate Cancer
Prostate Cancer Metastatic

Interventions

DRUG: Administering Lutetium-177-PSMA-617 (PLUVICTO)

Sponsor

Ebrahim S Delpassand